Niagen Bioscience (NAGE) Change in Accured Expenses (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Change in Accured Expenses of -$101000.0 for Q1 2026, down 108.19% year-over-year from $1.2 million in Q1 2025, and down 110.54% quarter-over-quarter from $958000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Change in Accured Expenses for 15 consecutive years, with -$101000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 108.19% year-over-year to -$101000.0; the TTM figure through Mar 2026 stood at $507000.0 (down 65.44% YoY), while the FY2025 annual figure was $1.8 million, up 52.65% from the prior year.
- Change in Accured Expenses declined to -$101000.0 in Q1 2026 per NAGE's latest filing, from $958000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.6 million in Q1 2022 and bottomed at -$1.8 million in Q2 2024.
- Historically, Change in Accured Expenses has averaged $350470.6 across 5 years, with a median of $958000.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 1756.67% — and 2024, when it sank 247.27%.
- Niagen Bioscience's Change in Accured Expenses stood at $581000.0 in 2022, then tumbled by 48.36% to $300000.0 in 2023, then soared by 269.0% to $1.1 million in 2024, then dropped by 13.46% to $958000.0 in 2025, then tumbled by 110.54% to -$101000.0 in 2026.
- Business Quant data shows NAGE's Change in Accured Expenses at -$101000.0 in Q1 2026, $958000.0 in Q4 2025, and $1.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | -3.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.78 Mn |
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | 958,000.00 |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 971,000.00 |
| Jun 30, 2024 | -1.84 Mn |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | -531,000.00 |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 581,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | -1.43 Mn |
| Mar 31, 2022 | 1.65 Mn |
| Dec 31, 2021 | 150,000.00 |
| Sep 30, 2021 | 762,000.00 |